In a report released yesterday, Thomas Flaten from Lake Street maintained a Buy rating on Achieve Life Sciences (ACHV – Research Report), with a price target of $19.00. The company’s shares opened today at $5.08.
Flaten covers the Healthcare sector, focusing on stocks such as Assertio Therapeutics, Checkpoint Therapeutics, and Castle Biosciences. According to TipRanks, Flaten has an average return of -7.9% and a 26.60% success rate on recommended stocks.
Achieve Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $24.67, a 385.63% upside from current levels. In a report released yesterday, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $35.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Achieve Life Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $9 million. In comparison, last year the company had a GAAP net loss of $7.6 million
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACHV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More on ACHV:
- Achieve Life Sciences (ACHV) Q2 Earnings Cheat Sheet
- Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast
- Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)
- Achieve Life Sciences announces publication of Phase 3 ORCA-2 trial results
